Results 41 to 50 of about 3,972 (148)

Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH)

American Journal of Hematology, EarlyView.
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac, Audrey Bidet, Elise Chapiro, Nathalie Douet‐Guilbert, Jean‐Baptiste Gaillard, Nada Assaf, Nathalie Auger, Hend Chaker, Jasmine Chauzeix, Inge Govaerts, Hippolyte Guérineau, Christine Lefebvre, Pauline Roynard, Hélène Guermouche, Lucienne Michaux, Marie‐Bérengère Troadec, Lauren Véronèse   +16 more
wiley   +1 more source

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials [PDF]

, 2020
BACKGROUND: The selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients.
Rohrberg, Kristoffer S, Childs, Barrett H, Hong, David S, Hyman, David M, van Tilburg, Cornelis M, Federman, Noah, Mascarenhas, Leo, Dowlati, Afshin, Pappo, Alberto S, Laetsch, Theodore W, Pfister, Stefan M, Witt, Olaf, DuBois, Steven G, Doz, François, Albert, Catherine M, Schilder, Russell J, McDermott, Ray, Farago, Anna F, Ladanyi, Marc, Drilon, Alexander, Nanda, Shivani, Nagasubramanian, Ramamoorthy, Rudzinski, Erin R, Tahara, Makoto, Patel, Jyoti D, Berlin, Jordan D, Bielack, Stefan, Geoerger, Birgit, Kummar, Shivaani   +28 more
core   +1 more source

From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis

Frontiers in Pharmacology
Introduction: The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions has facilitated the development of precision oncology. Two first-generation NTRK inhibitors (larotrectinib and entrectinib) are currently approved for the treatment ...
Zhiwei Cui, Zhen Zhai, De Xie, Lihui Wang, Feiyan Cheng, Siyu Lou, Fan Zou, Rumeng Pan, Shixue Chang, Haoyan Yao, Jing She, Yidan Zhang, Xinyuan Yang   +12 more
doaj   +1 more source

A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report

BMC Pulmonary Medicine, 2021
Background The identification of NTRK fusions in tumours has become critically important due to the actionable events predictive of response to TRK inhibitor.
Lei Zhang, Huanhuan Liu, Ye Tian, Huina Wang, Xueying Yang   +4 more
doaj   +1 more source

Larotrectinib in Patients With Tumors With <i>NTRK</i> Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E. [PDF]

JCO Precis Oncol
PURPOSE: Recurrent chromosomal fusions in neurotrophic tropomyosin receptor kinase (NTRK) have been reported as an oncogenic driver across human cancer.
Akhave N, Song Z, Hong DS, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Takebe N, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT.   +17 more
europepmc   +2 more sources

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source

Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene

Frontiers in Oncology, 2023
Significant improvements in the survival rates of paediatric cancer have been achieved over the past decade owing to recent advances in therapeutic and diagnostic strategies.
Catherine Cervi, Catherine Cervi, Zoltán Sápi, Gábor Bedics, Gábor Bedics, Erik Zajta, Erik Zajta, Lajos Hegyi, Lajos Hegyi, Judit Pápay, Katalin Dezső, Edit Varga, Katalin Mudra, Csaba Bödör, Csaba Bödör, Monika Csóka   +15 more
doaj   +1 more source

Genetic Mutations in Recurrent/Metastatic Papillary Thyroid Carcinoma

The Laryngoscope, EarlyView.
We investigated the mutational landscape and prognostic implications of recurrent/metastatic papillary thyroid carcinoma using nationwide C‐CAT data from 348 patients. CDKN2A, KMT2D, and concurrent TERT/BRAF mutations were independently associated with poorer overall survival, highlighting the potential prognostic value of comprehensive genomic ...
Hiromi Nagano, Satoshi Kiyama, Takayuki Kyutoku, Masaru Yamashita   +3 more
wiley   +1 more source

Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib

, 2022
Fusions of NTRK (neurotrophic tyrosine receptor kinase) genes with 5' partner genes can result in the expression of chimeric proteins that drive oncogenesis through ligand-independent kinase activation.
Van Cutsem, Eric, Peeters , Marc, Peeters, Marc, Cuppens, Kristof, Clement, Paul M., De Wilde, Bram, Pauwels , Patrick, Machiels, Jean Pascal, Machiels, Jean-Pascal, Awada, Ahmad, Pauwels, Patrick, Rottey, Sylvie, Van Cutsem , Eric, Berghmans, Thierry, Peeters, Michel, Clement, Paul M J P.   +15 more
core   +1 more source